Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other Accumulated Expenses (2016 - 2025)

Conmed (CNMD) has disclosed Other Accumulated Expenses for 16 consecutive years, with $138.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 26.18% year-over-year to $138.5 million, compared with a TTM value of $138.5 million through Dec 2025, up 26.18%, and an annual FY2025 reading of $138.5 million, up 26.18% over the prior year.
  • Other Accumulated Expenses was $138.5 million for Q4 2025 at Conmed, up from $130.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $163.5 million in Q3 2023 and bottomed at $62.5 million in Q1 2022.
  • Average Other Accumulated Expenses over 5 years is $108.9 million, with a median of $112.7 million recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses soared 104.31% in 2023, then decreased 29.29% in 2024.
  • Year by year, Other Accumulated Expenses stood at $65.7 million in 2021, then skyrocketed by 50.17% to $98.7 million in 2022, then skyrocketed by 53.76% to $151.7 million in 2023, then fell by 27.63% to $109.8 million in 2024, then increased by 26.18% to $138.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CNMD at $138.5 million in Q4 2025, $130.7 million in Q3 2025, and $125.1 million in Q2 2025.